Home » Myriad Presents Initial Phase IIa Data for Metastatic Melanoma Agent
Myriad Presents Initial Phase IIa Data for Metastatic Melanoma Agent
Myriad Pharmaceuticals, Inc. … announced the presentation of initial clinical data from an ongoing Phase 2a study of Azixa, a microtubule destabilizing
agent in stage 4 melanoma patients.
StreetInsider
StreetInsider
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May